therapure bio contact presentation sept 29 08

1

BioContact Presentation | Fall 2008www.therapurebio.com

2

13/ of all newproducts

The future of medicine

2

3

$51B

$87B

$25B

$89B

2001

Protein therapeutic market

2005 2010 2010

Worldwide mobile technology market

4

You discovered a protein with blockbuster potential

Specific

Safe

Targeted

Efficacious

Novel

4

5

Ultimately, to get your product approved you will invest…

You are working hard to develop it

5

11 years 5 clinical trials 2,000 patients 39 patents ~$1 billion

66

What about manufacturing?

What about manufacturing?

7

Discovery Development

Marketing Manufacturing 7

8

Scaling up is not easy

Simple

Quick

Inexpensive

Milligrams

commercialbench

Complex

Long lead times - 4-5 years

Expensive -

$150+ million

Kilograms

8

9

Therapure Biopharma:Overcoming the manufacturing barrier

Complex We know protein purification

Long lead times Ready to go now

Quality cGMP compliant

Expensive Established Meadowpine Facility

Regulated We have 8 INDs under our belts

9

10

your trusted partneryour trusted partner

10

for protein manufacturin

g

for protein manufacturin

g

1111

Therapure Biopharma Focus

Provide clients accessto our biomanufacturing capabilities

– Product development– Protein purification – Cell culture– Formulation– Fill– Lyophilization – Finishing

Advance our pipeline• TBI 301

Post-liver transplant & acute and chronic HCV

• TBI 302 Hepatocellular carcinoma & metastatic colorectal cancer

• TBI 303 Proprietary protein modification technology

• TBI 304 Chemotherapy-induced anemia

1212

Experienced Management Team

• Thomas Wellner President and CEO

• Dirk AlkemaVice President, Operations

• Peter Winkley Vice President Finance and Chief Financial Officer

• David Bell Vice President, Drug Development and Chief Scientific Officer

13

About Us

Therapure Biopharma Inc. Canadian-based privately held biopharmaceutical company wholly owned by Catalyst Fund Limited Partnership II and management.

Catalyst Fund Limited Partnership IIA private equity fund with over $1B U.S. in capital that is managed by The Catalyst Capital Group Inc., a Toronto based private equity fund manager.

1414

Ideally located

15

90 minute flight to

60% of the U.S. population15

16

Our Unique and Flexible

Biomanufacturing Facility

16

17

130,000 square feet

5,700 sq.ft. of research laboratories

6,300 sq.ft. of QC labs

30,000 sq.ft. clean room manufacturing

28,000 sq.ft. controlled cGMP warehouse

2,200 sq.ft. GMP clinical pilot suites

18

Large Volume Protein Purification

18

19

Large Scale Processing Capabilities

19

20

Large Volume Storage Capacity

20

21

Central Service Chase

21

22

CIP Units For Process Equipment

22

23

Water For Injection

23

24

Purified Water System

24

25

Clean Rooms and Access Pointsto Meet cGMP Requirements

25

26

QC Laboratories

26

27

Sterile Fill Suite

27

28

Support Beyond Manufacturing

28

29

Biomanufacturing In-licensing Equity partnerships

• Late-stage products

• Approved products in new indications

• Possible targeted investment

Joint development• Innovative financing

• Product co-development

• Process development

• Formulation

• Protein purification

• Fill & finishing

Fee for service

Enhanced partnerships

29

30

Therapure(manufacturing)

Therapure(finance)

$$ (seed capital)

$$ (development fees)

protein product

interest/options

30

Biotech

Equity Partnership

30

31

partnership

Biotech

Therapure Biopharma

Product IP/development

Manufacturing IP/development

31

Joint Development

31

32

Therapure Biopharma Inc.

• Unique and Flexible– Scale of production– Range of production

• Expertise– Scientific– Manufacturing– Regulatory

• Financing opportunities

3333

LetLet

bring your biopharmaceutical to the world!

bring your biopharmaceutical to the world!

www.therapurebio.com